The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
In a single year, Rodger Novakโs gene-editing startup raised $89 million in venture funding, got $105 million to enter a partnership with big drugmaker Vertex Pharmaceuticals Inc. โย and, this week, announced a deal with Bayer AG worth $335 million.
Crispr Therapeutics Ltd. wonโt start human trials of its therapies until 2017, but the company is at the forefront of one of the hottest technologies in biotech. Investors and drugmakers from Johnson & Johnson to Merck & Co. are flocking to a potent tool called Crispr, saying its precise DNA editing capabilities could yield treatments for conditions as diverse as blood diseases, cancers, auto-immune disorders and genetic eye disorders.
Gene-editing companies have drawn more than $1 billion in venture dollars since 2013, according to Boston Consulting Group, from traditional biotech venture capitalists like Deerfield Management Co. and Polaris Partners, and names better known in in the tech world, such as Bill Gates and Khosla Ventures.ย Demand to participate in Crispr Therapeuticsโ funding round was so strong that the company turned away some blue-chip investors, Novak said in an interview.
Share this article
Like many promising new technologies that came before it, Crispr has yet to prove it will be effective at creating new medicine. And the idea of editing genes has made some ethicists queasy, though the companies getting funding arenโt making alterations in human sperm, eggs or embryos, which would be controversial.
Read full, original post:ย The Gene-Editing Tool on Every Drugmaker’s Wish List This Year
